Competition & Markets Authority
Illumina’s takeover of PacBio raises competition concerns
Illumina’s proposed takeover of PacBio raises competition concerns in the supply of specialist DNA sequencing systems in the UK, a CMA investigation has found.
The Competition and Markets Authority (CMA) has been investigating the proposed $1.2 billion merger of Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio). The companies are both global suppliers of DNA sequencing systems to organisations across the world, including UK universities, laboratories and research institutes. DNA sequencing systems are used to study genetic variation in humans and other species for purposes such as advanced disease research and drug development.
After completing its initial Phase 1 investigation, the CMA has concerns that the deal could remove potentially the most significant competitive threat to Illumina. Illumina is by far the largest supplier of DNA sequencing systems, both in the UK and worldwide, and the merging businesses are already close competitors. PacBio has also recently released a new, innovative system for DNA sequencing (the “Sequel II” instrument), which means that it is well-positioned to offer stronger competition to Illumina in the future.
Aside from the merging parties, there are limited alternatives available for customers at present. While some suppliers plan to enter the market in future, it is not clear when they will enter or how competitive their technology will be.
The CMA is therefore concerned that Illumina could face insufficient competition after acquiring PacBio and that the deal could result in more expensive or lower quality products and less innovation in the market.
If the merging businesses are unable to address the CMA’s concerns, the deal will be referred for an in-depth Phase 2 investigation, to be carried out by a group of independent CMA panel members.
For more information, visit the Illumina, Inc. / Pacific Biosciences of California, Inc. merger inquiry page.
Latest News from
Competition & Markets Authority
Facebook and eBay pledge to combat trading in fake reviews09/01/2020 09:20:00
Following action from the CMA, Facebook and eBay have committed to combatting the trade of fake and misleading reviews on their sites.
Illumina/PacBio abandon merger03/01/2020 10:20:00
Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
LN-Gaiety’s purchase of MCD cleared by CMA20/12/2019 12:20:00
An in-depth CMA investigation has found that Live Nation-Gaiety’s proposed purchase of MCD does not raise competition concerns.
CMA lifts the lid on digital giants18/12/2019 13:20:00
The CMA has published an update in its examination of online platforms and digital advertising, uncovering new detail about how the sector’s biggest names operate.
Estate agents fined over half a million pounds for price fixing18/12/2019 09:10:00
3 Berkshire estate agents have been fined more than £600,000 for illegally fixing the minimum commission rates they charged their customers.
Pharmaceutical merger cleared by CMA16/12/2019 11:25:00
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Amazon’s Deliveroo investment raises competition concerns12/12/2019 11:20:00
Amazon’s investment in Deliveroo raises serious competition concerns for UK customers that may require an in-depth investigation by the CMA.
CMA Statement on design, construction and fit-out services director disqualification11/12/2019 12:20:00
Individual directors should be held accountable if their company breaks competition law.